Fig. 1

LRRK2-IN-1 suppresses the IL-1β-induced inflammation and catabolism and induces anabolism without causing the inhibition of chondrocyte viability. A Schematic diagram of cell treatment and experimental procedures. B Cell viability assessed by CCK8 assay. No obvious inhibition of chondrocyte proliferation was observed when treated with 0.5, 1.0, 2.5, and 5.0 µM LRRK2-IN-1 for 24 h. Data represent mean ± SD; N = 6/group; one-way ANOVA; ns, not significant. C Western blot analyses of the protein levels of anabolic, catabolic, inflammatory factors in the IL-1β-induced chondrocytes treated with 0.5, 1.0, 2.5, and 5.0 µM LRRK2-IN-1 for 24 h. LRRK2-IN-1 suppressed MMP3, MMP13, iNOS, and COX2 and induced COL2 and SOX9 in a dose-dependent manner. D Quantitative analyses of the western blot results. Data represent mean ± SD; N = 3/group; *P < 0.05; **P < 0.01 by one-way ANOVA. E Immunofluorescence of iNOS, MMP13, and aggrecan expression in the IL-1β-induced chondrocytes treated with 5.0 µM LRRK2-IN-1 for 24 h. Scar bar: 400 μm